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Summary Sixty infants with birth-weights less than
1500 g and who were less than 6 h old were
randomly assigned to a group given phenobarbitone or a
control group. Intravenous phenobarbitone was given in
doses sufficient to achieve anticonvulsant serum levels within
12-18 h. Maintenance therapy was continued for one week.
Periventricular/intraventricular haemorrhage (IVH)
occurred in 13 3% (4/30) of the phenobarbitone group and in
46.7% (14/30) of the control group. The occurrence of risk
factors related to IVH was similar in the two groups.
Phenobarbitone may reduce the incidence of IVH in small
preterm infants.
Introduction
THE reported incidence ofperiventricular/intraventricular
haemorrhage (IVH) in preterm infants is 40-43%.1,2
Haemorrhages usually occur on the 2nd or 3rd postnatal day3
and may by asymptomatic. 1,2 The major sites of involvement
are the periventricular germinal matrix and the lateral
ventricles.4 Prevention of IVH has been based upon good
supportive care and avoidance of risk factors associated with
IVH, such as the rapid infusion of sodium bicarbonate. 5
Specific intervention has not been studied in a controlled
manner.
The potential neuroprotective benefits of barbiturates’-21
have been investigated in animal experiments and in
uncontrolled studies in adults. We investigated the use of
phenobarbitone for the prevention of IVH in preterm infants
in a randomised, controlled study. We chose to evaluate
phenobarbitone rather than a short-acting barbiturate
because of the availability of pharmacokinetic data on this
drug and extensive experience with its use in neonates.
Methods
The investigation was approved by the Committee for Clinical
Research and Investigation Involving Human Beings, University of
Michigan Medical Center. Informed consent was obtained from a
’Presented at the Annual Meeting of the American Pediatric Society and the
Society for Pediatric Research, San Francisco, California on April 29, 1981.
parent of each infant before enrolment in the study, which took
place from April, 1980, to March, 1981.
Infants were eligible for the study if they weighed less than 1500 g
at birth, had no obvious congenital malformations, were admitted to
our neonatal intensive-care unit within the first 6 h of life, and had
mothers who had not taken barbiturates during pregnancy.
Infants were randomly assigned by lottery (sampling without
replacement) to treatment or control groups. The treatment group
received phenobarbitone according to the following protocol: two
loading doses of 10 mg/kg each were administered intravenously
12 h apart; maintenance doses of 2 - 5 mg/kg every 12 h were begun
12 h after the second loading dose and were continued intra-
venously, intramuscularly, or orally for 6 days. Steady-state serum
concentrations were achieved on the 3rd postnatal day and dosages
were adjusted to maintain levels in the 20-30 g/ml range. At the
end of the 7th day therapy was stopped.
We performed bedside cranial ultrasonography by means of a
portable real-time sector scanner (Mark III Real-Time Imager,
Advanced Technology Laboratories, Bellevue, WA 98005 U.S.A.)
and a trans-fontanelle approach24 on fifty-one of the sixty infants on
the 3rd, 4th, or 5th postnatal day. The nine remaining infants died
before the 3rd postnatal day and a postmortem examination was
performed. Ultrasound scans were interpreted by at least two
ultrasonographers, who did not know which infants had received
phenobarbitone. In three cases the ultrasonographers did not agree
on the presence of IVH; computed axial tomography (EMI 1005
Head Scanner, EMI Medical U.S.A.) was performed in these
infants. Neuroradiologists were also not informed about which
infants had received phenobarbitone. Studies were repeated when-
ever an infant had clinical or laboratory evidence suggestive of IVH.
Haemorrhages were graded according to the system proposed by
Papile et al.’ 1
We reviewed the case-reports after discharge or death of the
infants to determine the variables which may have influenced the
development ofIVH.25-27
Results
Two-tailed Student’s t-test analyses did not demonstrate
any significant differences in birth-weights, gestational ages,
or Apgar scores between the two groups. Nor were there any
significant differences in sex distribution or survival rates as
determined by X analysis (table l). Postmortem examination
was performed on fourteen of the fifteen who died. Seven of
the dead infants had IVH. We did not believe that IVH had
been the main cause of death in these infants. Death in the
fourteen infants was attributed to hyaline membrane disease
(seven cases), sepsis (six cases), and bronchopulmonary
dysplasia with sepsis (one case). In addition, there were no
statistically significant differences between the groups with
respect to mode of delivery or place of delivery (inborn versus
transport).
IVH occurred in 13. 3% (4/30) of infants in the pheno-
barbitone group and 46-7% (14/30) of infants in the
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TABLE I-BIRTH DATA, APGAR SCORES, AND SURVIVAL
None of the differences between the phenobarbitone and control groups was
significant.
*Inborn.
untreated group (p<0 -01,=7- 94). The incidence of IVH
in the control group was similar to that diagnosed by
computed tomography cited in previous reports. 1,2
Table II gives the clinical and laboratory data on the
eighteen infants with IVH. Patient 18 died before receiving
the second loading dose of phenobarbitone and thus a steady-
state concentration had not been achieved.
Both groups required the same degree of ventilatory
support. The percentage of infants in each group
experiencing at least one episode of hyperoxia, hypoxia,
hypercapnia, hypocapnia, acidosis, or hypotension was
similar (table III). Hypotension was defined as a systolic
blood-pressure at least 10 mm Hg below the expected value,28
or clinical evidence of impaired perfusion. Pressures were
measured every hour by the non-invasive doppler technique
(’Dinamap’, Model 84712005, Critikon, Tampa, Florida) or
by direct umbilical-artery manometry. Sodium bicarbonate
and blood-volume expanders (blood or colloid, 10 ml/kg,
infused within 30 min) were administered to both groups
with comparable frequency. Though differences in these
factors might have been expected, the close similarities
between the groups emphasises the findings of Lazzara et al.
that only half the cases of haemorrhage can be correctly
predicted from clinical findings.29
TABLE III-RESPIRATORY AND METABOLIC DATA IN BOTH GROUPS
None of the differences between the two groups was significant.
The mean steady-state serum phenobarbitone concen-
tration, determined in twenty-five infants, was 26-6&plusmn;6’5 
J.lg/ml (range 15-9-39-6 g/ml). Five infants died before
maintenance therapy had been initiated. Seizures were not
observed in any of the infants in the treatment group; in one
infant in the control group seizures developed after IVH had
been diagnosed and phenobarbitone was then given. None of
the infants on phenobarbitone became hypotensive.
Five eligible infants admitted to the neonatal intensive-care
unit during the study period were not enrolled. One infant
died before random allocation to treatment, and the parents of
four infants did not consent to the study.
Discussion
The results of this randomised, controlled study suggest
that phenobarbitone may reduce the incidence of IVH in
preterm infants. The following mechanisms of
neuroprotection mediated by barbiturates have been
proposed: decreased cerebral metabolic rate,6-11 decreased
catecholamine release., 12-1 ’ "free-radical" inactivation,15
decreased intracellular and extracellular oedema,16-18
anticonvulsant effect, 19,2 decreased intracranial pressure, 21
sedative effect,22 and enzyme induction.23 Since the
pathogenesis of IVH is complex, the benefits provided by
phenobarbitone probably involve - several of these
mechanisms.
TABLE 11-SUMMARY OF DATA ON PATIENTS WITH IVH
PM = postmortem examination; US = cranial ultrasonography; CT = computed tomography. *Age at death.
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We felt that it was reasonable to begin this investigation
with anticonvulsant doses of phenobarbitone, since the
resultant serum level should have predictable and slight side-
effects and might still provide neuroprotection. The dosage
schedule selected was based on the report of Lockman et al. 30
Since IVH often occurs before 24 h of age, 31 we limited the
study to infants to whom we could administer
phenobarbitone before they were 6 h old. We timed the dose
intervals so as to achieve loading 12 h after the start of
phenobarbitone treatment. This schedule should establish
the desired phenobarbitone serum level before the time at
which IVH is most likely to occur. 3 Eight infants (five
treatment, three control) died before they were 18 hold ; IVH
occurred in one treated infant and in three controls. The
statistical significance of the difference between the two
groups is not changed if these patients are removed from the
analysis. However, the relatively high incidence of early IVH
indicates that dosages and dose intervals should be more
closely investigated. Side-effects were not evident in any of
the infants on phenobarbitone. In particular, respiratory
depression and hypotension were no more common in
treatment infants than in control infants (table III).
Although a brief course of phenobarbitone treatment in the
neonatal period has no known long-term effects upon
cognitive development, we intend to follow-up the infants in
this study. We will evaluate infant development and cognitive
function, and perform routine medical and neurological
assessments. The ability of phenobarbitone to prevent IVH
in the population studied is promising, since it suggests that
the occurrence of haemorrhage can be modified by drug
therapy in the first hours of life. However, before we can
recommend phenobarbitone treatment of infants at risk for
IVH we need to know what the long-term outcome is in those
who have received phenobarbitone treatment as infants.
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Summary High concentrations of vasoactive intestinal
polypeptide (VIP) were detected by
immunocytochemistry and radioimmunoassay in thirty
surgical specimens of male external genitalia. VIP was found
exclusively in fine autonomic nerves. VIPergic nerves were
most densely concentrated in the penis around the pudendal
arteries and in the erectile tissue of the corpus cavernosum.
Considerable numbers of VIP nerve fibres were also seen in
the vas deferens and epididymis. VIP is known to exert
regulatory actions on blood-flow, secretion, and muscle tone.
Its presence in considerable amounts in the male genital tract
suggests that this newly discovered peptide neurotransmitter
may be important in the nervous control of male external
genitalia.
*J. G. is a visiting colleague from Peking Medical College, Peoples’ Republic
of China.
Introduction
VASOACTIVE intestinal polypeptide (VIP) is a newly
discovered regulatory peptide composed of 28 aminoacids.1 It
relaxes smooth muscle and is a powerful vasodilator. It also
stimulates secretion in the pancreas and intestine.2 VIP has
been demonstrated, by the use of specific antibodies, in
autonomic nerves supplying many peripheral tissues. 3
VIPergic nerves form a major part of the newly recognised
class of non-adrenergic non-cholinergic (peptidergic) nerves.
Despite these discoveries, little attention has been paid to the
